Alan Musso

Alan Musso

Chief Financial OfficeratFulcrum Therapeutics· In proxies 2023–2025

Pay in FY2025+44% from the year before · Fulcrum Therapeutics stock +140.6% the same year

Alan Musso was paid $1.8M in FY2025 (Dec), up 44%. Fulcrum Therapeutics stock rose 140.6% that year.

Pay$100 in the stock at the end of FY22 → $155
Pay is from the Summary Compensation Table of each Fulcrum Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Fulcrum TherapeuticsPublic company · 3 yr
    • Chief Financial Officer2023 – Present · 3 yrStock in role -38%
  2. Rein Therapeutics, Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?